Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126682 · ClinicalTrials.gov registry record · Phase 4
Effect of Bupropion on Seizure Threshold in Depressed Patients
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT03126682 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 10 participants.
The verdict
NCT03126682, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the effect of bupropion on seizure threshold and duration in depressed patients receiving right unilateral ultra-brief electroconvulsive therapy (ECT). The investigators plan to recruit 10 patients into the study, administer sustained release (SR) bupropion 4 hours prior to receiving ECT. The investigators plan to compare the seizure threshold and seizure durations between ECT sessions with and without bupropion administration. The study's implication is to examine how ECT can be optimized by rational combination with medications that lower seizure threshold.
Interventions
- DRUG Wellbutrin SR 300Mg Extended-Release Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-08-25 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03126682
The ClinicalTrials.gov registry entry for NCT03126682 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Wellbutrin SR 300Mg Extended-Release Tablet is the first listed.
NCT03126682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03126682 about?
NCT03126682 is a clinical study titled "Effect of Bupropion on Seizure Threshold in Depressed Patients". The purpose of the study is to examine the effect of bupropion on seizure threshold and duration in depressed patients receiving right unilateral ultra-brief electroconvulsive therapy (ECT). The investigators plan to recruit 10 patients into the study, administer sustained release (SR) bupropion 4 h...
What is the current status of trial NCT03126682?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2017-08-25. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT03126682?
The interventions under investigation include: Wellbutrin SR 300Mg Extended-Release Tablet (DRUG).
Who is sponsoring clinical trial NCT03126682?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.